Leverage advanced, organotypic 3D liver microtissues to assess mitochondrial liabilities
- Combine 3D InSight™ Human Liver Microtissues with label-free assessment of oxygen consumption rate (OCR) with the Agilent XFe96 Analyzer
- Identify mitochondrial liabilities with high sensitivity and specificity in a primary 3D liver model with 4x higher spare respiratory capacity (SRC) than 2D monolayer hepatocyte cultures
- Enable study of long-term drug exposure effects with repeat dosing in highly predictive two-step assay
Service at a Glance
Two-step workflow for 3D InSight™ Mitochondrial Toxicity Testing includes the initial drug exposure phase followed by independent OCR assessment on the Agilent XFe96 Analyzer and ATP cell viability assay.
SRC assessment in primary human hepatocytes grown in 3D (green) vs. 2D (blue). The 4X greater SRC of 3D microtissues more closely reflects that of in vivo liver.
The bioenergetics profile of 4 independent analysis runs (each run contained at least 3 replicates) of untreated 3D InSight™ Human Liver Microtissues was analyzed. The overall standard deviations (indicated by green shading) across all runs were 4-10%. The mean across assays and replicates is displayed as a black dotted line.
Based on the ratio of IC50SRC to IC50ATP, compounds are classified based on hepatotoxic and mitotoxic liabilities.